Viking Therapeutics (VKTX) Price & Analysis

Compare

6,403 Followers

VKTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$18.92 - $81.73

Previous CloseN/A

Volume7.75M

Average Volume (3M)3.84M

Market Cap

$3.83B

Enterprise Value$2.16B

Total Cash (Recent Filing)$33.88M

Total Debt (Recent Filing)$878.00K

Price to Earnings (P/E)―

Beta1.97

Next Earnings

Oct 22, 2025

EPS Estimate

-0.67

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.58

Shares Outstanding112,444,960

10 Day Avg. Volume4,262,649

30 Day Avg. Volume3,842,412

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.57

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-24.88K

Enterprise Value/Ebitda-10.18

Forecast

1Y Price Target

$92.42

Price Target Upside171.58% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressViking has fully enrolled the Phase 2 study for the oral VK2735, indicating strong interest and progress in development.

Market PotentialThe GLP-1/obesity/metabolic market could support multiple players, and Viking is believed to have a 'best-in-class' compound that could compete commercially if approved.

Strategic PartnershipsVKTX's newly announced manufacturing and supply agreement with CordenPharma will provide ample production of both SC and oral VK2735 across autoinjector, vial/syringe, and tablet formulations.

Bears Say

M&A OutlookThe announced supply agreement with CordenPharma is perceived to make near-term M&A less likely, contributing to the current weakness in shares.

R&D ExpensesViking's R&D expenses increased by 152% YoY, mainly due to increased spending for clinical trials and manufacturing.

Viking Therapeutics News

Viking Therapeutics call volume above normal and directionally bullish

Bullish option flow detected in Viking Therapeutics (VKTX) with 17,623 calls trading, 1.4x expected, and implied vol increasing...

13h ago

VKTX

BofA defends Eli Lilly following selloff on weight loss pill trial data

Shares of Eli Lilly (LLY) are underperforming on Thursday after the company reported quarterly results and announced data...

16h ago

LLY

NVO

Wainwright says Viking’s VK2735 holds strong as competitor data raises eyebrows

H.C. Wainwright analyst Joseph Pantginis believes Viking Therapeutics’ (VKTX) VK2735 remains a standout among competitors after Eli Lilly’s...

17h ago

LLY

VKTX

These 3 Stocks Are Screaming ‘Strong Buy,’ According to the Technical Analysis

As markets remain shaky, technical analysis helps investors find good stock opportunities. Using TipRanks’ Technical Analysis Screener, we...

3d ago

ACLX

JAZZ

Viking Therapeutics price target raised to $38 from $31 at Citi

Citi raised the firm’s price target on Viking Therapeutics (VKTX) to $38 from $31 and keeps a Neutral...

15d ago

VKTX

Viking Therapeutics reports Q2 EPS (58c), consensus (44c)

“The Viking team achieved significant execution and clinical milestones during the first half of 2025,” stated Brian Lian,...

15d ago

VKTX

Viking Therapeutics reports Q2 EPS (58c), consensus (44c)

“The Viking team achieved significant execution and clinical milestones during the first half of 2025,” stated Brian Lian,...

15d ago

VKTX

Viking Therapeutics options imply 10.2% move in share price post-earnings

Pre-earnings options volume in Viking Therapeutics (VKTX) is 1.5x normal with calls leading puts 7:2. Implied volatility suggests...

16d ago

VKTX

Options Volatility and Implied Earnings Moves This Week, July 21 – July 24, 2025

This week, several major companies will be reporting earnings. Among them are Tesla (TSLA), Alphabet Class A (GOOGL),...

18d ago

Promising Phase 1 Results for Viking Therapeutics’ VK2735 Justify Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Viking Therapeutics, retaining the price target of...

17h ago

VKTX

Viking Therapeutics: A Promising Buy with Strategic Opportunities in Obesity Treatment and Direct-to-Consumer Market

William Blair analyst Andy Hsieh has maintained their bullish stance on VKTX stock, giving a Buy rating on...

6d ago

VKTX

Viking Therapeutics Stock Soars Amid Clinical Progress

Viking Therapeutics ( ($VKTX) ) has risen by 7.76%. Read on to learn why. Viking Therapeutics has seen...

13d ago

VKTX

Viking Therapeutics Receives Buy Rating Amid Promising Clinical Developments and Strategic Initiatives

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Viking Therapeutics yesterday and set a price target...

14d ago

VKTX

Viking Therapeutics’ Earnings Call: Clinical Advances Amid Financial Challenges

Viking Therapeutics (($VKTX)) has held its Q2 earnings call. Read on for the main highlights of the call....

14d ago

VKTX

VKTX FAQ

What was Viking Therapeutics’s price range in the past 12 months?

Viking Therapeutics lowest stock price was $18.92 and its highest was $81.73 in the past 12 months.

What is Viking Therapeutics’s market cap?

Viking Therapeutics’s market cap is $3.83B.

When is Viking Therapeutics’s upcoming earnings report date?

Viking Therapeutics’s upcoming earnings report date is Oct 22, 2025 which is in 75 days.

How were Viking Therapeutics’s earnings last quarter?

Viking Therapeutics released its earnings results on Jul 24, 2025. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.446 by -$0.134.

Is Viking Therapeutics overvalued?

According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Viking Therapeutics pay dividends?

Viking Therapeutics does not currently pay dividends.

What is Viking Therapeutics’s EPS estimate?

Viking Therapeutics’s EPS estimate is -0.67.

How many shares outstanding does Viking Therapeutics have?

Viking Therapeutics has 112,444,960 shares outstanding.

What happened to Viking Therapeutics’s price movement after its last earnings report?

Viking Therapeutics reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.446. Following the earnings report the stock price went up 2.746%.

Which hedge fund is a major shareholder of Viking Therapeutics?

Currently, no hedge funds are holding shares in VKTX

Viking Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-19.99%

Trailing 12-Months

Asset Growth

-12.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics (VKTX) Earnings & Revenues

Historic Earnings Reports

VKTX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed picture with significant clinical progress and a strong cash position highlighting the positives. However, increased net losses and rising expenditures underscore financial challenges. The call reflects a balanced perspective of achievements and operational costs.View all VKTX earnings summaries

VKTX Stock 12 Month Forecast

Average Price Target

$92.42

▲(171.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","48":"$48","74":"$74","100":"$100","126":"$126"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$92.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,48,74,100,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.68,39.78153846153846,46.88307692307692,53.98461538461538,61.08615384615385,68.18769230769232,75.28923076923077,82.39076923076922,89.49230769230769,96.59384615384616,103.69538461538463,110.79692307692306,117.89846153846153,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.68,37.27538461538462,41.87076923076923,46.466153846153844,51.06153846153846,55.65692307692308,60.252307692307696,64.84769230769231,69.44307692307692,74.03846153846155,78.63384615384615,83.22923076923077,87.82461538461538,{"y":92.42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.68,33.08923076923077,33.49846153846154,33.90769230769231,34.316923076923075,34.72615384615385,35.135384615384616,35.54461538461538,35.95384615384615,36.363076923076925,36.77230769230769,37.18153846153846,37.59076923076923,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.65,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.12,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.24,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.87,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >